Saturday, October 3, 2026
ExploreSearch
Via News
MarketFX

USD/CNH Went Down By Over 4% In The Last 21 Sessions

ViaNews Editorial Team

February 20, 2023

USD/CNH Went Down By Over 4% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 4.32% for the last 21 sessions. At 02:12 EST on Monday, 20 February, USD/CNH (USDCNH) is $6.86.

USD/CNH's yearly highs and lows, it's 0.048% up from its 52-week low and 0.28% down from its 52-week high.

News about

  • Eur/usd stays defensive around 1.0700 ahead of eurozone pmis, fed minutes. According to FXStreet on Sunday, 19 February, "Also important will be Thursday's second reading of the US fourth quarter (Q4) Gross Domestic Product, to direct immediate EUR/USD moves.", "A clear downside break of a three-month-old ascending trend line, now immediate resistance around 1.0730, keeps EUR/USD bears hopeful."
  • Eur/usd price analysis: remains pressured towards 1.0630-15 support area. According to FXStreet on Monday, 20 February, "In a case where EUR/USD remains firmer past 1.0710, the odds of witnessing a north-run towards the monthly high of 1.1033 can't be ruled out.", "With this, the EUR/USD bears are all set to revisit the 1.0630-15 support area comprising multiple levels marked since early January 2023."
  • Eur/usd aims to recapture 1.0700 as risk appetite recovers, fed minutes in focus. According to FXStreet on Monday, 20 February, "The EUR/USD pair has attempted a recovery after dropping to near 1.0673 in the early European session. "

More news about USD/CNH (USDCNH).

Categories

MarketFX

Tags

ForexForeign Exchange MarketCurrenciesUSDCNHUSD/CNHPrice DownFOREX Price DownForex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com